Product NDC: | 0078-0181 |
Proprietary Name: | Sandostatin |
Non Proprietary Name: | octreotide acetate |
Active Ingredient(s): | 100 ug/mL & nbsp; octreotide acetate |
Administration Route(s): | INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0078-0181 |
Labeler Name: | Novartis Pharmaceuticals Corporation |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA019667 |
Marketing Category: | NDA |
Start Marketing Date: | 19881021 |
Package NDC: | 0078-0181-01 |
Package Description: | 10 AMPULE in 1 PACKAGE (0078-0181-01) > 1 mL in 1 AMPULE (0078-0181-61) |
NDC Code | 0078-0181-01 |
Proprietary Name | Sandostatin |
Package Description | 10 AMPULE in 1 PACKAGE (0078-0181-01) > 1 mL in 1 AMPULE (0078-0181-61) |
Product NDC | 0078-0181 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | octreotide acetate |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 19881021 |
Marketing Category Name | NDA |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | OCTREOTIDE ACETATE |
Strength Number | 100 |
Strength Unit | ug/mL |
Pharmaceutical Classes | Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] |